Bonraybio Co., Ltd. (TPE:6955)
Taiwan · Delayed Price · Currency is TWD 166.00
0.00 (0.00%)
At close: Mar 27, 2026
Bonraybio Revenue
In the year 2025, Bonraybio had annual revenue of 306.31M TWD with 37.43% growth. Bonraybio had revenue of 82.23M in the quarter ending December 31, 2025, with 30.48% growth.
Revenue
306.31M
Revenue Growth
+37.43%
P/S Ratio
13.44
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 306.31M | 83.43M | 37.43% |
| Dec 31, 2024 | 222.88M | 63.24M | 39.61% |
| Dec 31, 2023 | 159.64M | 53.37M | 50.22% |
| Dec 31, 2022 | 106.27M | 49.98M | 88.78% |
| Dec 31, 2021 | 56.30M | 29.71M | 111.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hi-Clearance | 4.28B |
| Wellell | 2.40B |
| InnoCare Optoelectronics | 2.29B |
| OK Biotech | 1.56B |
| Dynamic Medical Technologies | 1.39B |
| WeLeader Biomedical | 1.11B |
| A Plus Biotechnology | 835.89M |
| Delta Asia International | 694.15M |